PDCD1 and cancer: In recent decades, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized the treatment landscape for patients with advanced cancer (1).